glaxosmithkline ihc limited
glaxosmithkline ihc limited Company Information
Company Number
07257967
Next Accounts
Sep 2025
Industry
Other financial service activities, except insurance and pension funding, (not including security dealing on own account and factoring) n.e.c.
Shareholders
glaxosmithkline finance plc
Group Structure
View All
Contact
Registered Address
79 new oxford street, london, WC1A 1DG
Website
http://gsk.comglaxosmithkline ihc limited Estimated Valuation
Pomanda estimates the enterprise value of GLAXOSMITHKLINE IHC LIMITED at £0 based on a Turnover of £0 and 1.3x industry multiple (adjusted for size and gross margin).
glaxosmithkline ihc limited Estimated Valuation
Pomanda estimates the enterprise value of GLAXOSMITHKLINE IHC LIMITED at £102.9m based on an EBITDA of £22.4m and a 4.59x industry multiple (adjusted for size and gross margin).
glaxosmithkline ihc limited Estimated Valuation
Pomanda estimates the enterprise value of GLAXOSMITHKLINE IHC LIMITED at £300.5m based on Net Assets of £233.5m and 1.29x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Glaxosmithkline Ihc Limited Overview
Glaxosmithkline Ihc Limited is a live company located in london, WC1A 1DG with a Companies House number of 07257967. It operates in the financial intermediation not elsewhere classified sector, SIC Code 64999. Founded in May 2010, it's largest shareholder is glaxosmithkline finance plc with a 100% stake. Glaxosmithkline Ihc Limited is a established, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Glaxosmithkline Ihc Limited Health Check
There is insufficient data available to calculate a health check for Glaxosmithkline Ihc Limited. Company Health Check FAQs
0 Strong
0 Regular
3 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Ihc Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Glaxosmithkline Ihc Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Ihc Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Ihc Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (14)
- Glaxosmithkline Ihc Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Glaxosmithkline Ihc Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Glaxosmithkline Ihc Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Ihc Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Ihc Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Ihc Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (30 weeks)
- - Glaxosmithkline Ihc Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 99%, this is a higher level of debt than the average (70.2%)
- - Glaxosmithkline Ihc Limited
- - Industry AVG
GLAXOSMITHKLINE IHC LIMITED financials
Glaxosmithkline Ihc Limited's latest turnover from December 2023 is 0 and the company has net assets of £233.5 million. According to their latest financial statements, we estimate that Glaxosmithkline Ihc Limited has 1 employee and maintains cash reserves of £146 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income Or Grants | 0 | 0 | ||||||||||||
| Cost Of Sales | 0 | 0 | ||||||||||||
| Gross Profit | 0 | 0 | ||||||||||||
| Admin Expenses | -7,060,000 | 0 | ||||||||||||
| Operating Profit | 7,060,000 | 15,764,000 | 5,366,000 | 11,738,000 | 11,331,000 | 92,699,000 | -63,000 | -497,000 | -146,000 | -78,000 | 0 | |||
| Interest Payable | 1,124,284,000 | 329,619,000 | 0 | 0 | 36,151,000 | 26,776,000 | 18,141,000 | 29,746,000 | 71,943,000 | 46,108,000 | 2,125,000 | 837,000 | 142,000 | 33,000 |
| Interest Receivable | 1,143,793,000 | 352,251,000 | 0 | 0 | 50,682,000 | 33,068,000 | 31,196,000 | 41,127,000 | 164,829,000 | 108,751,000 | 3,786,000 | 3,418,000 | 858,000 | 107,000 |
| Pre-Tax Profit | 17,308,000 | 14,987,000 | 7,060,000 | 15,764,000 | 12,482,000 | 5,366,000 | 11,738,000 | 11,331,000 | 92,699,000 | 62,580,000 | 1,164,000 | 2,435,000 | 638,000 | 74,000 |
| Tax | -3,909,000 | -2,824,000 | -1,386,000 | -2,997,000 | -2,272,000 | -995,000 | -2,257,000 | -2,229,000 | -18,794,000 | -13,429,000 | -271,000 | -597,000 | -169,000 | -21,000 |
| Profit After Tax | 13,399,000 | 12,163,000 | 5,674,000 | 12,767,000 | 10,210,000 | 4,371,000 | 9,481,000 | 9,102,000 | 73,905,000 | 49,151,000 | 893,000 | 1,838,000 | 469,000 | 53,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 13,399,000 | 12,163,000 | 5,674,000 | 12,767,000 | 10,210,000 | 4,371,000 | 9,481,000 | 9,102,000 | 73,905,000 | 49,151,000 | 893,000 | 1,838,000 | 469,000 | 53,000 |
| Employee Costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Number Of Employees | ||||||||||||||
| EBITDA* | 7,060,000 | 15,764,000 | 5,366,000 | 11,738,000 | 11,331,000 | 92,699,000 | -63,000 | -497,000 | -146,000 | -78,000 | 0 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 3,323,971,000 | 2,352,711,000 | 231,350,000 | 75,879,000 | 67,709,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 3,323,971,000 | 2,352,711,000 | 231,350,000 | 75,879,000 | 67,709,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 19,638,825,000 | 23,626,843,000 | 18,394,442,000 | 12,731,208,000 | 7,765,612,000 | 7,064,996,000 | 3,882,638,000 | 12,893,689,000 | 9,842,674,000 | 35,708,357,000 | 334,616,000 | 263,380,000 | 165,489,000 | 105,650,000 |
| Misc Debtors | 0 | 0 | 5,655,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 146,026,000 | 315,918,000 | 494,417,000 | 1,120,379,000 | 470,343,000 | 412,310,000 | 236,852,000 | 500,882,000 | 290,064,000 | 495,379,000 | 351,193,000 | 392,679,000 | 44,298,000 | 37,086,000 |
| misc current assets | 2,770,000 | 10,291,000 | 0 | 5,714,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 19,787,621,000 | 23,953,052,000 | 18,894,514,000 | 13,857,301,000 | 8,235,955,000 | 7,477,306,000 | 4,119,490,000 | 13,394,571,000 | 10,132,738,000 | 36,203,736,000 | 685,809,000 | 656,059,000 | 209,787,000 | 142,736,000 |
| total assets | 23,111,592,000 | 26,305,763,000 | 19,125,864,000 | 13,933,180,000 | 8,303,664,000 | 7,477,306,000 | 4,119,490,000 | 13,394,571,000 | 10,132,738,000 | 36,203,736,000 | 685,809,000 | 656,059,000 | 209,787,000 | 142,736,000 |
| Bank overdraft | 40,997,000 | 252,972,000 | 403,590,000 | 955,715,000 | 313,753,000 | 0 | 0 | 0 | 0 | 195,253,000 | 139,997,000 | 165,841,000 | 10,000 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 22,832,791,000 | 25,827,912,000 | 18,498,544,000 | 12,772,313,000 | 7,798,230,000 | 7,106,121,000 | 3,815,675,000 | 13,047,931,000 | 9,752,818,000 | 35,912,656,000 | 512,299,000 | 457,209,000 | 179,086,000 | 112,662,000 |
| other short term finances | 424,000 | 1,978,000 | 0 | 0 | 0 | 190,902,000 | 126,684,000 | 178,963,000 | 204,842,000 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 3,904,000 | 2,824,000 | 15,816,000 | 2,912,000 | 2,208,000 | 1,020,000 | 2,239,000 | 2,266,000 | 18,769,000 | 13,423,000 | 260,000 | 649,000 | 169,000 | 21,000 |
| total current liabilities | 22,878,116,000 | 26,085,686,000 | 18,917,950,000 | 13,730,940,000 | 8,114,191,000 | 7,298,043,000 | 3,944,598,000 | 13,229,160,000 | 9,976,429,000 | 36,121,332,000 | 652,556,000 | 623,699,000 | 179,265,000 | 112,683,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 22,878,116,000 | 26,085,686,000 | 18,917,950,000 | 13,730,940,000 | 8,114,191,000 | 7,298,043,000 | 3,944,598,000 | 13,229,160,000 | 9,976,429,000 | 36,121,332,000 | 652,556,000 | 623,699,000 | 179,265,000 | 112,683,000 |
| net assets | 233,476,000 | 220,077,000 | 207,914,000 | 202,240,000 | 189,473,000 | 179,263,000 | 174,892,000 | 165,411,000 | 156,309,000 | 82,404,000 | 33,253,000 | 32,360,000 | 30,522,000 | 30,053,000 |
| total shareholders funds | 233,476,000 | 220,077,000 | 207,914,000 | 202,240,000 | 189,473,000 | 179,263,000 | 174,892,000 | 165,411,000 | 156,309,000 | 82,404,000 | 33,253,000 | 32,360,000 | 30,522,000 | 30,053,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 7,060,000 | 15,764,000 | 5,366,000 | 11,738,000 | 11,331,000 | 92,699,000 | -63,000 | -497,000 | -146,000 | -78,000 | 0 | |||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | -3,909,000 | -2,824,000 | -1,386,000 | -2,997,000 | -2,272,000 | -995,000 | -2,257,000 | -2,229,000 | -18,794,000 | -13,429,000 | -271,000 | -597,000 | -169,000 | -21,000 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -3,016,758,000 | 7,348,107,000 | 5,824,360,000 | 4,973,766,000 | 768,325,000 | 3,182,358,000 | -9,011,051,000 | 3,051,015,000 | -25,865,683,000 | 35,373,741,000 | 71,236,000 | 97,891,000 | 59,839,000 | 105,650,000 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 1,080,000 | -12,992,000 | 12,904,000 | 704,000 | 1,188,000 | -1,219,000 | -27,000 | -16,503,000 | 5,346,000 | 13,163,000 | -389,000 | 480,000 | 148,000 | 21,000 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -5,805,782,000 | -4,960,295,000 | -3,179,206,000 | 9,020,505,000 | -3,058,416,000 | 25,944,934,000 | -35,374,070,000 | -72,393,000 | -98,154,000 | -59,938,000 | -105,650,000 | |||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | -2,995,121,000 | 7,329,368,000 | 5,726,231,000 | 4,974,083,000 | 692,109,000 | 3,290,446,000 | -9,232,256,000 | 3,295,113,000 | -26,159,838,000 | 35,400,357,000 | 55,090,000 | 278,123,000 | 66,424,000 | 112,662,000 |
| Other Short Term Loans | -1,554,000 | 1,978,000 | 0 | 0 | -190,902,000 | 64,218,000 | -52,279,000 | -25,879,000 | 204,842,000 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 19,509,000 | 22,632,000 | 0 | 0 | 14,531,000 | 6,292,000 | 13,055,000 | 11,381,000 | 92,886,000 | 62,643,000 | 1,661,000 | 2,581,000 | 716,000 | 74,000 |
| cash flow from financing | -2,977,166,000 | 7,353,978,000 | 5,726,231,000 | 4,974,083,000 | 515,738,000 | 3,360,956,000 | -9,271,480,000 | 3,280,615,000 | -25,862,110,000 | 35,463,000,000 | 56,751,000 | 280,704,000 | 67,140,000 | 142,736,000 |
| cash and cash equivalents | ||||||||||||||
| cash | -169,892,000 | -178,499,000 | -625,962,000 | 650,036,000 | 58,033,000 | 175,458,000 | -264,030,000 | 210,818,000 | -205,315,000 | 144,186,000 | -41,486,000 | 348,381,000 | 7,212,000 | 37,086,000 |
| overdraft | -211,975,000 | -150,618,000 | -552,125,000 | 641,962,000 | 313,753,000 | 0 | 0 | 0 | -195,253,000 | 55,256,000 | -25,844,000 | 165,831,000 | 10,000 | 0 |
| change in cash | 42,083,000 | -27,881,000 | -73,837,000 | 8,074,000 | -255,720,000 | 175,458,000 | -264,030,000 | 210,818,000 | -10,062,000 | 88,930,000 | -15,642,000 | 182,550,000 | 7,202,000 | 37,086,000 |
glaxosmithkline ihc limited Credit Report and Business Information
Glaxosmithkline Ihc Limited Competitor Analysis
Perform a competitor analysis for glaxosmithkline ihc limited by selecting its closest rivals, whether from the FINANCIAL AND INSURANCE ACTIVITIES sector, other established companies, companies in WC1A area or any other competitors across 12 key performance metrics.
glaxosmithkline ihc limited Ownership
GLAXOSMITHKLINE IHC LIMITED group structure
Glaxosmithkline Ihc Limited has no subsidiary companies.
Ultimate parent company
2 parents
GLAXOSMITHKLINE IHC LIMITED
07257967
glaxosmithkline ihc limited directors
Glaxosmithkline Ihc Limited currently has 5 directors. The longest serving directors include Mr Adam Walker (Jun 2015) and Mrs Ciara Lynch (Mar 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Adam Walker | 57 years | Jun 2015 | - | Director | |
| Mrs Ciara Lynch | England | 56 years | Mar 2020 | - | Director |
| Mr Alistair Davidson | United Kingdom | 52 years | Sep 2020 | - | Director |
| Mr Alistair Davidson | United Kingdom | 52 years | Sep 2020 | - | Director |
| Mr Timothy Woodthorpe | United Kingdom | 46 years | Dec 2023 | - | Director |
P&L
December 2023turnover
0
0%
operating profit
22.4m
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
233.5m
+0.06%
total assets
23.1b
-0.12%
cash
146m
-0.54%
net assets
Total assets minus all liabilities
glaxosmithkline ihc limited company details
company number
07257967
Type
Private limited with Share Capital
industry
64999 - Other financial service activities, except insurance and pension funding, (not including security dealing on own account and factoring) n.e.c.
incorporation date
May 2010
age
15
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
DELOITTE LLP
address
79 new oxford street, london, WC1A 1DG
Bank
-
Legal Advisor
-
glaxosmithkline ihc limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to glaxosmithkline ihc limited.
glaxosmithkline ihc limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for GLAXOSMITHKLINE IHC LIMITED. This can take several minutes, an email will notify you when this has completed.
glaxosmithkline ihc limited Companies House Filings - See Documents
| date | description | view/download |
|---|
